Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
If you are switching to tirzepatide after semaglutide failure, audit your stress levels honestly
For individuals seeking medically supervised weight management, there are several MHRA-approved options available in the UK that offer a robust evidence base and established safety profiles
Book your consultation today Frequently Asked Questions 1
Of these trials, four compared DPP-4 inhibitors against placebo (SAVOR-TIMI 53, EXAMINE, TECOS, CARMELINA), eight compared GLP-1RA against placebo (ELIXA, LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND, PIONEER 6, AMPLITUTE-O) and eleven compared SGLT-2 inhibitors against placebo (EMPA-REG, CANVAS, DECLARE, CREDENCE, DAPA-HF, DAPA CKD, VERTIS-CV, EMPEROR-R, SCORED, SOLOIST-WHF, EMPEROR-P)
No dose adjustment is required for semaglutide or tirzepatide based on kidney function, even in severe chronic kidney disease or end-stage renal disease
Moore, K
